🦈 This is a sponsored post. For more information, please visit this page.
According to a statement, the scientist following Pfizer and BioNTech’s COVID-19 vaccine remarks that he foresees it to “bash the virus over the head,” assuring it would end the pandemic.
The said vaccine, known as BNT162b2, was reported as 92% effective in concluding trials from the Phase 3 clinical study on 43,538 enrolled participants. It would prevent them from getting sick, based on the first interim analysis administered last week by the independent Data Monitoring Committee (DMC).
“Today is a great day for science and humanity. The first set of results from our Phase 3 COVID-19 vaccine trial provides the initial evidence of our vaccine’s ability to prevent COVID-19,” claimed Pfizer CEO and Chairman Dr. Albert Bourla, in a statement.
He also emphasized his confidence regarding the treatment’s effectiveness because it ‘attacks’ the virus on increased levels. His team knew that vaccines could beat the coronavirus. According to Pfizer’s official website, the analysis evaluated 94 confirmed cases of COVID-19 in the announced participants.
It was also stated that the security for safety is completed 28 days after the vaccination, which comprises a 2-dose schedule. The final effectiveness of vaccine results may modify as the study proceeds. The organization is looking forward to presenting added efficacy and safety data from thousands of cooperators in the following weeks.
“We are reaching this critical milestone in our vaccine development program at a time when the world needs it most with infection rates setting new records, hospitals nearing over-capacity, and economies struggling to reopen. With Today’s news, we are a significant step closer to providing people around the world with a much-needed breakthrough to help bring an end to this global health crisis… I want to thank the thousands of people who volunteered to participate in the clinical trial, our academic collaborators and investigators at the study sites, and our colleagues and collaborators around the world who are dedicating their time to this crucial endeavor. We could not have come this far without the tremendous commitment of everyone involved.”Dr. Albert Bourla
Fortunately, the DMC has not recorded unspecified vaccine complications. They prescribed that the research advance in collecting further protection data, which would be discussed universally with professionals.
Additionally, thousands of participants will remain monitored for long-term assurance and observation for two years following their secondary treatment.
“Based on current projections, we expect to produce globally up to 50 million vaccine doses in 2020 and up to 1.3 billion doses in 2021.”Dr. Albert Bourla